Log In
BCIQ
Print this Print this
 

Migranal

  Manage Alerts
Collapse Summary General Information
Company Valeant Pharmaceuticals International Inc.
DescriptionDihydroergotamine (DHE) mesylate nasal spray
Molecular Target
Mechanism of Action 
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentMarketed
Standard IndicationMigraine
Indication DetailsTreat migraine
Regulatory Designation
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

2

$3,200.0M

$3,200.0M

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

07/15/2013

Undisclosed

0

Undisclosed

10/04/2010

$3,200.0M

$3,200.0M

0

Get a free BioCentury trial today